See the latest news and media coverage for Natera. We track all announcements, press releases, and industry mentions in real time, all in one place.
Molecular diagnostics company specializing in cell-free DNA testing
natera.comLast updated
In short: Natera reported Q2 revenue growth, won FDA breakthrough status for MCED, and advanced Signatera in Japan.
PMDA authorized Signatera as a companion diagnostic for muscle-invasive bladder cancer supporting adjuvant atezolizumab decisions with commercial launch expected in H1 2027.
Total revenues grew 37.7% to $752.8 million, oncology volume rose 57.2%, and the company raised annual revenue guidance.
Revenue reached $753 million, a 38% increase. The company raised its full-year outlook by $100 million and posted significant volume growth across oncology and women's health segments.
First FDA-approved blood-based MRD test to guide treatment decisions in muscle-invasive bladder cancer, enabling precision for MRD-positive patients while sparing negative patients.
The US Food and Drug Administration (FDA) has granted Breakthrough Device designation to Natera's multi-cancer early ...
Natera's Signatera test secured a key regulatory approval, while Cantor raised its sales expectations for Omeros' lead drug, Yartemlea.
For Q2 2026, Natera, Inc. Common Stock reported EPS of -$0.47, beating estimates by 6.67%, and revenue of $752.75M, 11.7% above expectations. How did the...
In women's health, Natera launched an enhanced Panorama NIPT in May, slashing its no‑call rate to about 0.5% from roughly 2%. Prospective blinded data on...
Track Natera and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Natera and other trending companies.
